Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Daniel J. Haraf and Ralph R. Weichselbaum.
|
|
Connection Strength |
|
 |
|
 |
|
2.826 |
|
|
|
-
Foster CC, Fan M, Lee NY, Yom SS, Heaton CM, Deraniyagala R, Amdur R, Weichselbaum RR, Haraf DJ. Is It Worth It? Consequences of Definitive Head and Neck Reirradiation. Semin Radiat Oncol. 2020 Jul; 30(3):212-217.
Score: 0.217
-
Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 1996 Apr; 2(4):755-62.
Score: 0.162
-
Haraf DJ, Rubin SJ, Sweeney P, Kuchnir FT, Sutton HG, Chodak GW, Weichselbaum RR. Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Aug 30; 33(1):3-14.
Score: 0.156
-
Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
Score: 0.119
-
Haraf DJ, Vokes EE, Panje WR, Weichselbaum RR. Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
Score: 0.119
-
Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
Score: 0.104
-
Haraf DJ, Weichselbaum RR. Treatment selection in T1 and T2 vocal cord carcinoma. Oncology (Williston Park). 1988 Oct; 2(10):41-50.
Score: 0.096
-
Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
Score: 0.095
-
Milano MT, Vokes EE, Kao J, Jackson W, List MA, Stenson KM, Witt ME, Dekker A, MacCracken E, Garofalo MC, Chmura SJ, Weichselbaum RR, Haraf DJ. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
Score: 0.081
-
Milano MT, Vokes EE, Salama JK, Stenson KM, Kao J, Witt ME, Mittal BB, Argiris A, Weichselbaum RR, Haraf DJ. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
Score: 0.075
-
Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
Score: 0.074
-
Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Portugal L, Pelzer H, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.069
-
Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, Haraf DJ. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003 Apr; 14(4):564-9.
Score: 0.066
-
Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.065
-
Mantz CA, Vokes EE, Stenson K, Kies MS, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
Score: 0.057
-
Mantz CA, Vokes EE, Kies MS, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ. Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol. 2001 Mar; 12(3):343-7.
Score: 0.057
-
Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R, Dolan ME, Pelzer H, Sulzen L, Witt ME, Hsieh YC, Mittal BB, Weichselbaum RR. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.053
-
Lee MM, Vokes EE, Rosen A, Witt ME, Weichselbaum RR, Haraf DJ. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999 Jul-Aug; 5(4):219-23.
Score: 0.051
-
Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
Score: 0.050
-
Haraf DJ, Kies M, Rademaker AW, Stenson K, Mittal B, Pelzer H, Wenig B, Witt ME, Sulzen L, Weichselbaum RR, Vokes EE. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
Score: 0.049
-
Haraf DJ, Stenson K, List M, Witt ME, Weichselbaum RR, Vokes EE. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
Score: 0.043
-
Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
Score: 0.042
-
Vokes EE, Haraf DJ, Stenson K, Stupp R, Malone D, Levin J, Weichselbaum RR. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
Score: 0.039
-
Vokes EE, Stupp R, Haraf D, Moran W, Malone D, Wenig B, Sweeney P, Weichselbaum RR. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):47-52.
Score: 0.038
-
Weichselbaum RR, Beckett MA, Vokes EE, Brachman DG, Haraf D, Hallahan D, Kufe D. Cellular and molecular mechanisms of radioresistance. Cancer Treat Res. 1995; 74:131-40.
Score: 0.037
-
Haraf DJ, Weichselbaum RR, Vokes EE. Timing and sequencing of chemoradiotherapy. Cancer Treat Res. 1995; 74:173-98.
Score: 0.037
-
Panje WR, Namon AJ, Vokes E, Haraf DJ, Weichselbaum RR. Surgical management of the head and neck cancer patient following concomitant multimodality therapy. Laryngoscope. 1995 Jan; 105(1):97-101.
Score: 0.037
-
Vokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
Score: 0.037
-
Sweeney PJ, Haraf DJ, Vokes EE, Dougherty M, Weichselbaum RR. Radiation therapy in head and neck cancer: indications and limitations. Semin Oncol. 1994 Jun; 21(3):296-303.
Score: 0.036
-
Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
Score: 0.034
-
Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993 Aug 15; 53(16):3667-9.
Score: 0.034
-
Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade⢠Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
Score: 0.032
-
Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D, Weichselbaum RR. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res. 1992 Sep 01; 52(17):4832-6.
Score: 0.032
-
Haraf DJ, Vokes EE, Weichselbaum RR, Panje WR. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
Score: 0.031
-
Vokes EE, Haraf DJ, Panje WR, Schilsky RL, Weichselbaum RR. Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
Score: 0.031
-
Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.030
-
Vokes EE, Haraf DJ, McEvilly JM, Mick R, Kozloff MF, Goldman MD, Moran WJ, Clendeninn NJ, Collier MA, Weichselbaum RR, et al. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
Score: 0.030
-
Vokes EE, Moormeier JA, Ratain MJ, Egorin MJ, Haraf DJ, Mick R, Weichselbaum RR. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
Score: 0.030
-
Haraf DJ, Drucker DR, Weichselbaum RR, Diamond AM. Radioresistant derivatives of radiosensitive CHO cells obtained following treatment with 5-azacytidine retain their sensitivity to cisplatin. Radiat Res. 1991 Aug; 127(2):226-9.
Score: 0.029
-
Springate SC, Haraf D, Weichselbaum RR. Temporal bone chemodectomas--comparing surgery and radiation therapy. Oncology (Williston Park). 1991 Apr; 5(4):131-7; discussion 140, 143.
Score: 0.029
-
Roeske JC, Chen GT, Atcher RW, Pelizzari CA, Rotmensch J, Haraf D, Montag A, Weichselbaum RR. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1539-48.
Score: 0.028
-
Rader JS, Haraf DJ, Halpern HJ, Rotmensch J, Spelbring DR, Sutton H, Javaheri G, Weichselbaum RR. Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience. J Surg Oncol. 1990 Jul; 44(3):157-65.
Score: 0.027
-
Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
Score: 0.026
-
Weichselbaum RR, Beckett MA, Simon MA, McCauley C, Haraf D, Awan A, Samuels B, Nachman J, Dritschilo A. In vitro radiobiological parameters of human sarcoma cell lines. Int J Radiat Oncol Biol Phys. 1988 Oct; 15(4):937-42.
Score: 0.024
-
Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.023
-
Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9.
Score: 0.020
-
Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, Brockstein BE, Mittal BB, Rademaker AW, Witt ME, Pelzer H, Weichselbaum RR, Vokes EE. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.017
-
Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, Chung T, Mittal BB, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
Score: 0.014
-
Connell PP, Ignacio L, Haraf D, Awan AM, Halpern H, Abdalla I, Nautiyal J, Jani AB, Weichselbaum RR, Vijayakumar S. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61.
Score: 0.014
-
Stenson KM, Haraf DJ, Pelzer H, Recant W, Kies MS, Weichselbaum RR, Vokes EE. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
Score: 0.014
-
Stenson KM, MacCracken E, List M, Haraf DJ, Brockstein B, Weichselbaum R, Vokes EE. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000 Mar; 126(3):371-7.
Score: 0.013
-
Lee JS, Jani AB, Pelizzari CA, Haraf DJ, Vokes EE, Weichselbaum RR, Chen GT. Volumetric visualization of head and neck CT data for treatment planning. Int J Radiat Oncol Biol Phys. 1999 Jun 01; 44(3):693-703.
Score: 0.013
-
Kies MS, Haraf DJ, Athanasiadis I, Kozloff M, Mittal B, Pelzer H, Rademaker AW, Wenig B, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
Score: 0.012
-
Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
Score: 0.012
-
Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
Score: 0.010
-
Wong WW, Mick R, Haraf DJ, Weichselbaum RR, Vokes EE. Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):153-62.
Score: 0.009
-
Rosen A, Vokes EE, Scher N, Haraf D, Weichselbaum RR, Panje WR. Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993 Jul; 119(7):743-6.
Score: 0.008
-
Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje WR, Wenig B, et al. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
Score: 0.008
-
Vokes EE, Haraf DJ, Weichselbaum RR, McEvilly JM, Sutton HG, Panje WR. Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1992 Aug; 19(4 Suppl 11):47-56.
Score: 0.008
-
Vokes EE, Weichselbaum RR, Mick R, McEvilly JM, Haraf DJ, Panje WR. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 1992 Jun 03; 84(11):877-82.
Score: 0.008
-
Halpern HJ, Jaffe DR, Nguyen TD, Haraf DJ, Spencer DP, Bowman MK, Weichselbaum RR, Diamond AM. Measurement of bioreduction rates of cells with distinct responses to ionizing radiation and cisplatin. Biochim Biophys Acta. 1991 Jul 10; 1093(2-3):121-4.
Score: 0.007
-
Jaffe DR, Haraf D, Schwartz JL, Weichselbaum RR, Diamond AM. Radioresistant derivatives of an X-ray-sensitive CHO cell line exhibit distinct patterns of sensitivity to DNA-damaging agents. Carcinogenesis. 1990 Aug; 11(8):1265-9.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|